Research programme: GPCR-uPAR - Science Park Raf/Heidelberg Pharma AG
Alternative Names: Research programme: anticancer therapeutics - Science Park Raf/Heidelberg Pharma; Signal transduction pathway inhibitors - Science Park Raf/Heidelberg PharmaLatest Information Update: 20 Nov 2017
At a glance
- Originator Science Park Raf
- Developer Science Park Raf; Wilex
- Class Antibodies
- Mechanism of Action G protein-coupled receptor antagonists; Signal transduction pathway inhibitors; Urokinase-type plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Feb 2005 Preclinical trials in Cancer in Germany (Parenteral)